Ingevity reports second quarter 2026 financial results
Key Terms
adjusted ebitda financial
free cash flow financial
net leverage financial
non-gaap financial measures financial
Second Quarter 2026 Results and Recent Highlights:
-
Net sales of
decreased$314.1 million 5% from prior year; excluding Road Markings, sales increased5% -
Net income from continuing operations of
, or$39.8 million per diluted share, compared to$1.13 , or$(141.4) million per diluted share, in the prior year$(3.87) -
Adjusted earnings from continuing operations of
and$61.5 million of adjusted diluted earnings per share compared to$1.74 and$44.9 million in the prior year$1.22 -
Adjusted EBITDA from continuing operations of
, up$115.0 million from the prior year; Adjusted EBITDA margin from continuing operations of$14.0 million 36.6% compared to30.5% in the prior year -
Completed the sale of Road Markings product line on April 15, 2026, for approximately
in net proceeds$63 million -
Raises full year Adjusted EBITDA outlook to a range of
to$380 following a solid start to the year$400 million
The results and guidance in this release include non-GAAP financial measures; see “Use of non‑GAAP financial measures” section for definitions and reconciliations to the most comparable GAAP measure. Unless otherwise stated, all comparisons below are made versus the same period in 2025 and are presented on a continuing operations basis.
Full Company Results
Net sales of
“We are delivering on the commitments we set at the beginning of the year," said Ingevity President and CEO Dave Li. "Strong commercial and operational execution across our businesses drove another strong quarter, giving us the confidence to raise our full-year diluted adjusted EPS and adjusted EBITDA guidance. While our outlook for the second half remains measured given the dynamic operating environment, our results reinforce the strength of the business and the progress we're making in building a stronger, more focused Ingevity. The completion of the Road Markings divestiture in April further demonstrates our commitment to portfolio transformation. We also continue to invest in organic growth opportunities that leverage our differentiated carbon technologies. Our recent municipal water treatment contract for PFAS filtration provides early commercial validation of our technology and demonstrates its potential to create attractive new growth opportunities in adjacent markets. Together, these actions are creating a stronger Ingevity: a more focused company with differentiated technology, attractive organic growth opportunities, and a stronger foundation for sustainable long-term shareholder value.”
Segment Results
Performance Materials
Performance Materials sales increased
Pavement Technologies
Pavement Technologies sales declined
Advanced Polymer Technologies
Advanced Polymer Technologies sales increased
Corporate and Other
Corporate and other expenses, which are not included in segment financial results, were
Liquidity/Other Continuing and Discontinued Operations
Second quarter operating cash flow was negative
Share repurchases totaled approximately
Full Year 2026 Outlook:
Following another strong quarter, the company is raising its full-year 2026 outlook while maintaining a measured view of the second half of the year. It now expects full year 2026 net sales between
Additional Information: The company will host a live webcast on Thursday, July 30, at 10:00 a.m. (Eastern) to discuss second quarter 2026 fiscal results. The webcast can be accessed via the Investor section of Ingevity’s website. Participants may pre-register for the event here.
Participants may also listen to the conference call by dialing 833 461 5787 (inside the
Instructions for accessing the webcast and conference call, along with a slide deck containing relevant financial and statistical information, will be posted to the Investors section of Ingevity’s website after the company issues its earnings release on July 29, 2026.
Ingevity: Purify, Protect and Enhance
Ingevity (NYSE: NGVT) is a global specialty materials company that develops advanced carbon and engineered materials solutions that improve mobility, strengthen and extend the life of infrastructure and enhance industrial processes. With a 90‑year legacy of innovation, we work closely with customers to solve technical challenges and deliver materials that improve performance and environmental outcomes in essential applications. Our portfolio includes Performance Materials activated carbon technologies for emissions control and filtration; Pavement Technologies solutions for high-performance pavement applications and dispersants for crop protection; and Advanced Polymer Technologies specialty polymers for coatings and industrial applications. Headquartered in
Use of non-GAAP financial measures: This press release includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not attempt to provide reconciliations of forward-looking non-GAAP guidance to the comparable GAAP measure because the impact and timing of the factors underlying the guidance assumptions are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, Ingevity believes such reconciliations would imply a degree of certainty that could be confusing to investors. |
Forward-looking statements: This press release contains “forward looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” “guidance,” “believes,” “anticipates” or similar expressions. Forward looking statements may include, without limitation, the potential benefits of any divestiture, acquisition or investment transaction, leadership transitions within our organization, expected financial positions, guidance, results of operations and cash flows; financing plans; business strategies and expectations; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; litigation-related strategies and outcomes; and markets for securities. Actual results could differ materially from the views expressed. Factors that could cause actual results to materially differ from those contained in the forward looking statements, or that could cause other forward looking statements to prove incorrect, include, without limitation, our ability to adjust our cost and operating structure after giving effect to any transaction that results from our announced review of strategic alternatives for our Advanced Polymer Technologies segment; adverse effects from general global economic, geopolitical and financial conditions beyond our control, including inflation, global trade tensions, and the |
INGEVITY CORPORATION |
||||||||||||||
Condensed Consolidated Statements of Operations (Unaudited) |
||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|||||||||||
In millions, except per share data |
2026 |
|
2025 |
|
2026 |
2025 |
||||||||
Net sales |
$ |
314.1 |
|
|
$ |
331.5 |
|
|
$ |
572.1 |
|
$ |
579.4 |
|
Cost of sales |
|
175.1 |
|
|
|
203.7 |
|
|
|
316.7 |
|
|
339.7 |
|
Gross profit |
|
139.0 |
|
|
|
127.8 |
|
|
|
255.4 |
|
|
239.7 |
|
Selling, general, and administrative expenses |
|
39.0 |
|
|
|
43.6 |
|
|
|
79.7 |
|
|
85.5 |
|
Research and technical expenses |
|
6.1 |
|
|
|
7.0 |
|
|
|
12.8 |
|
|
14.0 |
|
Restructuring and other (income) charges, net |
|
1.7 |
|
|
|
7.2 |
|
|
|
2.2 |
|
|
9.1 |
|
Goodwill impairment charge |
|
— |
|
|
|
183.8 |
|
|
|
— |
|
|
183.8 |
|
Long-lived asset impairment charge |
|
32.1 |
|
|
|
— |
|
|
|
32.1 |
|
|
— |
|
Other (income) expense, net |
|
(4.8 |
) |
|
|
4.2 |
|
|
|
17.6 |
|
|
8.3 |
|
Interest expense, net |
|
14.2 |
|
|
|
18.6 |
|
|
|
30.1 |
|
|
38.0 |
|
Income (loss) from continuing operations before income taxes |
|
50.7 |
|
|
|
(136.6 |
) |
|
|
80.9 |
|
|
(99.0 |
) |
Provision (benefit) for income taxes on continuing operations |
|
10.9 |
|
|
|
4.8 |
|
|
|
17.7 |
|
|
13.3 |
|
Net income (loss) from continuing operations |
|
39.8 |
|
|
|
(141.4 |
) |
|
|
63.2 |
|
|
(112.3 |
) |
Income (loss) from discontinued operations, net of income taxes |
|
(4.5 |
) |
|
|
(5.1 |
) |
|
|
31.9 |
|
|
(13.7 |
) |
Net income (loss) |
$ |
35.3 |
|
|
$ |
(146.5 |
) |
|
$ |
95.1 |
|
$ |
(126.0 |
) |
|
|
|
|
|
|
|
|
|||||||
Per share data |
|
|
|
|
|
|
|
|||||||
Basic earnings (loss) per share from continuing operations |
$ |
1.15 |
|
|
$ |
(3.87 |
) |
|
$ |
1.81 |
|
$ |
(3.08 |
) |
Basic earnings (loss) per share from discontinued operations |
|
(0.13 |
) |
|
|
(0.15 |
) |
|
|
0.91 |
|
|
(0.38 |
) |
Basic earnings (loss) per share |
$ |
1.02 |
|
|
$ |
(4.02 |
) |
|
$ |
2.72 |
|
$ |
(3.46 |
) |
|
|
|
|
|
|
|
|
|||||||
Diluted earnings (loss) per share from continuing operations |
$ |
1.13 |
|
|
$ |
(3.87 |
) |
|
$ |
1.78 |
|
$ |
(3.08 |
) |
Diluted earnings (loss) per share from discontinued operations |
|
(0.13 |
) |
|
|
(0.15 |
) |
|
|
0.89 |
|
|
(0.38 |
) |
Diluted earnings (loss) per share |
$ |
1.00 |
|
|
$ |
(4.02 |
) |
|
$ |
2.67 |
|
$ |
(3.46 |
) |
|
|
|
|
|
|
|
|
|||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|||||||
Basic |
|
34.7 |
|
|
|
36.5 |
|
|
|
35.0 |
|
|
36.4 |
|
Diluted |
|
35.3 |
|
|
|
36.5 |
|
|
|
35.6 |
|
|
36.4 |
|
INGEVITY CORPORATION |
|||||||||||||||
Segment Operating Results (Unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
In millions |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
Performance Materials |
$ |
160.6 |
|
|
$ |
153.9 |
|
|
$ |
316.0 |
|
|
$ |
300.7 |
|
Pavement Technologies |
|
104.2 |
|
|
|
134.3 |
|
|
|
162.5 |
|
|
|
193.2 |
|
Advanced Polymer Technologies |
|
49.3 |
|
|
|
43.3 |
|
|
|
93.6 |
|
|
|
85.5 |
|
Net sales |
$ |
314.1 |
|
|
$ |
331.5 |
|
|
$ |
572.1 |
|
|
$ |
579.4 |
|
|
|
|
|
|
|
|
|
||||||||
Performance Materials |
$ |
86.1 |
|
|
$ |
81.0 |
|
|
$ |
178.1 |
|
|
$ |
164.5 |
|
Pavement Technologies |
|
25.4 |
|
|
|
28.8 |
|
|
|
26.0 |
|
|
|
34.6 |
|
Advanced Polymer Technologies |
|
11.2 |
|
|
|
2.0 |
|
|
|
18.8 |
|
|
|
15.6 |
|
Segment EBITDA (1) |
$ |
122.7 |
|
|
$ |
111.8 |
|
|
$ |
222.9 |
|
|
$ |
214.7 |
|
Interest expense, net |
|
(14.2 |
) |
|
|
(18.6 |
) |
|
|
(30.1 |
) |
|
|
(38.0 |
) |
(Provision) benefit for income taxes on continuing operations |
|
(10.9 |
) |
|
|
(4.8 |
) |
|
|
(17.7 |
) |
|
|
(13.3 |
) |
Depreciation and amortization (2) |
|
(22.0 |
) |
|
|
(25.2 |
) |
|
|
(44.7 |
) |
|
|
(49.7 |
) |
Gain on sale of business (3) |
|
8.6 |
|
|
|
— |
|
|
|
8.6 |
|
|
|
— |
|
Restructuring and other income (charges), net (4) (5) |
|
(1.7 |
) |
|
|
(7.2 |
) |
|
|
(2.2 |
) |
|
|
(9.1 |
) |
Goodwill impairment charge (6) |
|
— |
|
|
|
(183.8 |
) |
|
|
— |
|
|
|
(183.8 |
) |
Long-lived asset impairment charge (6) |
|
(32.1 |
) |
|
|
— |
|
|
|
(32.1 |
) |
|
|
— |
|
Gain (loss) on strategic investment (4) (7) |
|
— |
|
|
|
(2.5 |
) |
|
|
— |
|
|
|
(2.5 |
) |
Litigation charge (8) |
|
— |
|
|
|
— |
|
|
|
(16.2 |
) |
|
|
— |
|
Impairment of license agreement (9) |
|
— |
|
|
|
— |
|
|
|
(2.8 |
) |
|
|
— |
|
Proxy contest charges (10) |
|
— |
|
|
|
(0.3 |
) |
|
|
— |
|
|
|
(8.2 |
) |
Portfolio realignment costs (11) |
|
(2.9 |
) |
|
|
— |
|
|
|
(6.1 |
) |
|
|
— |
|
Corporate and other (12) |
|
(7.7 |
) |
|
|
(7.8 |
) |
|
|
(16.4 |
) |
|
|
(16.2 |
) |
Indirect costs allocated to Divestiture (13) |
|
— |
|
|
|
(3.0 |
) |
|
|
— |
|
|
|
(6.2 |
) |
Net income (loss) from continuing operations |
$ |
39.8 |
|
|
$ |
(141.4 |
) |
|
$ |
63.2 |
|
|
$ |
(112.3 |
) |
| ____________________ | |
(1) |
Segment EBITDA is defined as segment net sales less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense associated with corporate debt facilities, interest income, income taxes, depreciation, amortization, gain on sale of business, restructuring and other income (charges), net, goodwill impairment charges, long-lived asset impairment charges, acquisition and other-related income (costs), gain (loss) on strategic investments, impairment of license agreement, proxy contest charges, portfolio realignment costs, pension and postretirement settlement and curtailment income (charges), net, litigation charge, indirect costs allocated to Divestiture, and Corporate and other costs. |
(2) |
The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such (income) charges to each respective reportable segment for which the charges relate. |
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
In millions |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Performance Materials |
$ |
11.1 |
|
$ |
9.9 |
|
$ |
22.0 |
|
$ |
19.8 |
Pavement Technologies |
|
3.5 |
|
|
6.0 |
|
|
7.0 |
|
|
11.9 |
Advanced Polymer Technologies |
|
7.4 |
|
|
8.3 |
|
|
15.7 |
|
|
16.0 |
Indirect costs allocated to Divestiture (i) |
|
— |
|
|
1.0 |
|
|
— |
|
|
2.0 |
Depreciation and amortization |
$ |
22.0 |
|
$ |
25.2 |
|
$ |
44.7 |
|
$ |
49.7 |
|
|
|
|
|
|
|
|||||
(i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment. |
|||||||||||
(3) |
The gain relates to the sale of our former Performance Chemicals' road markings product line on April 15, 2026. |
(4) |
For more information on these charges, refer to the Reconciliation of Adjusted Earnings table on page 8. |
(5) |
The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such (income) charges to each respective reportable segment for which the charges relate. |
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
In millions |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Performance Materials |
$ |
1.0 |
|
$ |
— |
|
$ |
1.5 |
|
$ |
— |
Pavement Technologies |
|
0.7 |
|
|
0.6 |
|
|
1.8 |
|
|
1.2 |
Advanced Polymer Technologies |
|
— |
|
|
5.9 |
|
|
(1.1) |
|
|
6.5 |
Indirect costs allocated to Divestiture |
|
— |
|
|
0.7 |
|
|
— |
|
|
1.4 |
Restructuring and other (income) charges, net |
$ |
1.7 |
|
$ |
7.2 |
|
$ |
2.2 |
|
$ |
9.1 |
(6) |
The company recorded a non-cash impairment charge within Advanced Polymer Technologies. |
(7) |
Charge relates to our Advanced Polymer Technologies reportable segment. |
(8) |
For information on our litigation charges please refer to Note 13, Commitments and Contingencies, in the Notes to the Condensed Consolidated Financial Statements included in the Company’s Form 10-Q for the quarter ended March 31, 2026, filed on May 7, 2026. Updates will be provided in subsequent filings of the Company's Form 10-Q in 2026. |
(9) |
Charge represents an impairment of a license agreement within our Performance Materials reportable segment. |
(10) |
Charges represent legal and other professional service fees as well as incremental proxy solicitation costs related to a proxy contest. |
(11) |
Charges represent professional service fees related to a review of the company's portfolio. |
(12) |
Corporate and other costs is defined as costs associated with corporate administrative functions (e.g., executive office, corporate finance, legal, human resources) and other compliance costs to operate as a NYSE listed entity. Also includes corporate administrative function share of information technology, safety, health, accounting and human resource departments. |
(13) |
Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment. |
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
In millions |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Cost of sales |
$ |
— |
|
$ |
1.2 |
|
$ |
— |
|
$ |
3.7 |
Selling, general, and administrative expenses |
|
— |
|
|
1.8 |
|
|
— |
|
|
2.5 |
Indirect costs allocated to Divestiture |
$ |
— |
|
$ |
3.0 |
|
$ |
— |
|
$ |
6.2 |
INGEVITY CORPORATION |
|||||
Condensed Consolidated Balance Sheets (Unaudited) |
|||||
In millions |
June 30, 2026 |
|
December 31, 2025 |
||
Assets |
|
|
|
||
Cash and cash equivalents |
$ |
97.4 |
|
$ |
78.1 |
Accounts receivable, net |
|
155.8 |
|
|
127.2 |
Inventories, net |
|
154.0 |
|
|
186.0 |
Restricted investment, net |
|
85.8 |
|
|
— |
Prepaid and other current assets |
|
50.8 |
|
|
47.0 |
Current assets of discontinued operations |
|
— |
|
|
15.9 |
Current assets |
|
543.8 |
|
|
454.2 |
Property, plant, and equipment, net |
|
575.0 |
|
|
608.1 |
Goodwill |
|
4.3 |
|
|
4.3 |
Other intangibles, net |
|
137.3 |
|
|
176.1 |
Deferred income taxes |
|
87.0 |
|
|
117.0 |
Restricted investment, net |
|
— |
|
|
84.4 |
Strategic investments |
|
83.4 |
|
|
83.1 |
Other assets |
|
106.7 |
|
|
104.4 |
Noncurrent assets of discontinued operations |
|
— |
|
|
19.5 |
Total Assets |
$ |
1,537.5 |
|
$ |
1,651.1 |
|
|
|
|
||
Liabilities |
|
|
|
||
Accounts payable |
$ |
88.0 |
|
$ |
92.0 |
Accrued expenses |
|
60.3 |
|
|
148.0 |
Notes payable and current maturities of long-term debt |
|
144.0 |
|
|
47.1 |
Other current liabilities |
|
45.3 |
|
|
51.1 |
Current liabilities of discontinued operations |
|
— |
|
|
3.1 |
Current liabilities |
|
337.6 |
|
|
341.3 |
Long-term debt including finance lease obligations |
|
1,056.2 |
|
|
1,161.4 |
Deferred income taxes |
|
44.2 |
|
|
55.1 |
Other liabilities |
|
52.6 |
|
|
62.9 |
Noncurrent liabilities of discontinued operations |
|
— |
|
|
0.7 |
Total Liabilities |
|
1,490.6 |
|
|
1,621.4 |
Equity |
|
46.9 |
|
|
29.7 |
Total Liabilities and Equity |
$ |
1,537.5 |
|
$ |
1,651.1 |
INGEVITY CORPORATION |
|||||||||||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
In millions |
2026 (1) |
|
2025 (1) |
|
2026 (1) |
|
2025 (1) |
||||||||
Cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
||||||||
Net income (loss) |
$ |
35.3 |
|
|
$ |
(146.5 |
) |
|
$ |
95.1 |
|
|
$ |
(126.0 |
) |
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
|
22.0 |
|
|
|
25.6 |
|
|
|
44.7 |
|
|
|
50.5 |
|
Restructuring and other (income) charges, net |
|
6.6 |
|
|
|
21.9 |
|
|
|
14.9 |
|
|
|
34.2 |
|
Impairment of license agreement |
|
— |
|
|
|
— |
|
|
|
2.8 |
|
|
|
— |
|
(Gain) loss on strategic investment |
|
— |
|
|
|
2.5 |
|
|
|
— |
|
|
|
2.5 |
|
Goodwill impairment charge |
|
— |
|
|
|
183.8 |
|
|
|
— |
|
|
|
183.8 |
|
Long-lived asset impairment charge |
|
32.1 |
|
|
|
— |
|
|
|
32.1 |
|
|
|
— |
|
(Gain) loss on sale of business |
|
(7.2 |
) |
|
|
— |
|
|
|
(62.8 |
) |
|
|
— |
|
Litigation charges |
|
— |
|
|
|
— |
|
|
|
16.2 |
|
|
|
— |
|
Other non-cash items |
|
15.5 |
|
|
|
3.5 |
|
|
|
41.8 |
|
|
|
11.1 |
|
Changes in operating assets and liabilities, net of effect of divestitures: |
|
|
|
|
|
|
|
||||||||
Restructuring and other cash outflow, net |
|
(6.8 |
) |
|
|
(11.5 |
) |
|
|
(15.4 |
) |
|
|
(23.1 |
) |
CTO resales cash inflow (outflow), net |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6.2 |
|
Litigation settlement payment |
|
(113.2 |
) |
|
|
— |
|
|
|
(113.2 |
) |
|
|
— |
|
Changes in other operating assets and liabilities, net |
|
1.9 |
|
|
|
(0.3 |
) |
|
|
(72.0 |
) |
|
|
(34.8 |
) |
Net cash provided by (used in) operating activities |
$ |
(13.8 |
) |
|
$ |
79.0 |
|
|
$ |
(15.8 |
) |
|
$ |
104.4 |
|
Cash provided by (used in) investing activities: |
|
|
|
|
|
|
|
||||||||
Capital expenditures |
$ |
(10.3 |
) |
|
$ |
(12.2 |
) |
|
$ |
(20.6 |
) |
|
$ |
(22.2 |
) |
Proceeds from sale of businesses |
|
63.2 |
|
|
|
— |
|
|
|
156.3 |
|
|
|
— |
|
Proceeds from Restricted investment |
|
23.1 |
|
|
|
— |
|
|
|
47.8 |
|
|
|
— |
|
Proceeds from disposition of assets |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3.6 |
|
Other investing activities, net |
|
(0.6 |
) |
|
|
9.4 |
|
|
|
(1.8 |
) |
|
|
4.3 |
|
Net cash provided by (used in) investing activities |
$ |
75.4 |
|
|
$ |
(2.8 |
) |
|
$ |
181.7 |
|
|
$ |
(14.3 |
) |
Cash provided by (used in) financing activities: |
|
|
|
|
|
|
|
||||||||
Proceeds from revolving credit facility and other borrowings |
$ |
163.7 |
|
|
$ |
66.2 |
|
|
$ |
877.5 |
|
|
$ |
158.5 |
|
Payments on revolving credit facility and other borrowings |
|
(167.6 |
) |
|
|
(129.0 |
) |
|
|
(885.6 |
) |
|
|
(229.3 |
) |
Debt issuance costs |
|
— |
|
|
|
— |
|
|
|
(4.0 |
) |
|
|
— |
|
Finance lease obligations, net |
|
(0.3 |
) |
|
|
(0.2 |
) |
|
|
(0.6 |
) |
|
|
(0.6 |
) |
Tax payments related to withholdings on vested equity awards |
|
(1.4 |
) |
|
|
— |
|
|
|
(5.7 |
) |
|
|
(2.6 |
) |
Proceeds and withholdings from share-based compensation plans, net |
|
2.5 |
|
|
|
— |
|
|
|
5.8 |
|
|
|
— |
|
Repurchases of common stock under stock repurchase plan |
|
(34.5 |
) |
|
|
— |
|
|
|
(86.8 |
) |
|
|
— |
|
Net cash provided by (used in) financing activities |
$ |
(37.6 |
) |
|
$ |
(63.0 |
) |
|
$ |
(99.4 |
) |
|
$ |
(74.0 |
) |
Increase (decrease) in cash, cash equivalents, and restricted cash |
|
24.0 |
|
|
|
13.2 |
|
|
|
66.5 |
|
|
|
16.1 |
|
Effect of exchange rate changes on cash |
|
1.6 |
|
|
|
3.0 |
|
|
|
1.8 |
|
|
|
4.4 |
|
Change in cash, cash equivalents, and restricted cash |
|
25.6 |
|
|
|
16.2 |
|
|
|
68.3 |
|
|
|
20.5 |
|
Cash, cash equivalents, and restricted cash at beginning of period |
|
155.3 |
|
|
|
90.9 |
|
|
|
112.6 |
|
|
|
86.6 |
|
Cash, cash equivalents, and restricted cash at end of period (2) |
$ |
180.9 |
|
|
$ |
107.1 |
|
|
$ |
180.9 |
|
|
$ |
107.1 |
|
|
|
|
|
|
|
|
|
||||||||
(1) The cash flows related to discontinued operations have not been segregated and remain included in the major classes of assets and liabilities. Accordingly, the Condensed Consolidated Statements of Cash Flows include the results of continuing and discontinued operations. |
|||||||||||||||
(2) Includes restricted cash of |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
Supplemental cash flow information: |
|
|
|
|
|
|
|
||||||||
Cash paid for interest, net of capitalized interest |
$ |
17.4 |
|
|
$ |
22.6 |
|
|
$ |
28.5 |
|
|
$ |
37.2 |
|
Cash paid for income taxes, net of refunds |
|
(5.2 |
) |
|
|
1.2 |
|
|
|
(2.7 |
) |
|
|
5.6 |
|
Purchases of property, plant, and equipment in accounts payable |
|
(1.1 |
) |
|
|
(0.6 |
) |
|
|
0.7 |
|
|
|
2.3 |
|
Leased assets obtained in exchange for new operating lease liabilities |
|
(0.9 |
) |
|
|
0.4 |
|
|
|
4.9 |
|
|
|
0.4 |
|
Ingevity Corporation
Non-GAAP Financial Measures
Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with
We believe these non-GAAP financial measures provide management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance, liquidity measures, and projected future results.
Ingevity uses the following non-GAAP measures:
Adjusted earnings (loss) from continuing operations is defined as net income (loss) from continuing operations plus restructuring and other (income) charges, net, goodwill impairment charges, long-lived asset impairment charge, acquisition and other-related (income) costs, pension and postretirement settlement and curtailment (income) charges, impairment of license agreement, debt refinancing fees, litigation charge, proxy contest charges, portfolio realignment costs, gain on sale of business, gain (loss) on strategic investment, and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.
Diluted adjusted earnings (loss) from continuing operations per share is defined as diluted earnings (loss) from continuing operations per share plus restructuring and other (income) charges, net, per share, acquisition and other-related (income) costs per share, pension and postretirement settlement and curtailment (income) charges per share, impairment of license agreement per share, debt refinancing fees per share, litigation charge per share, proxy contest charges per share, portfolio realignment costs per share, gain on sale of business per share, gain (loss) on strategic investment per share, goodwill impairment charge per share, long-lived asset impairment charge and the income tax expense (benefit) per share on those items, less the provision (benefit) from certain discrete tax items per share.
Adjusted EBITDA from continuing operations is defined as net income (loss) from continuing operations plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, acquisition and other-related (income) costs, litigation charge, impairment of license agreement, proxy contest charges, portfolio realignment costs, gain on sale of business, gain (loss) on strategic investment, goodwill impairment charge, long-lived asset impairment charge and pension and postretirement settlement and curtailment (income) charges, net.
Adjusted EBITDA from discontinued operations is defined as net income (loss) from discontinued operations plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, gain on sale of business.
Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations.
Adjusted EBITDA margin from continuing operations is defined as Adjusted EBITDA from continuing operations divided by Net sales from continuing operations.
Adjusted EBITDA margin from discontinued operations is defined as Adjusted EBITDA from discontinued operations divided by Net sales from discontinued operations.
Total Adjusted EBITDA Margin is defined as Total Adjusted EBITDA divided by Total net sales.
Total Net Sales is defined as Net sales from continuing operations and Net sales from discontinued operations.
Net Debt is defined as the sum of notes payable, short-term debt, current maturities of long-term debt and long-term debt including finance lease obligations less the sum of cash and cash equivalents, restricted cash associated with our new market tax credit financing arrangement, and restricted investment associated with certain finance lease obligations, excluding the allowance for credit losses on held-to-maturity debt securities held within the restricted investment.
Net Debt Ratio is defined as Net Debt divided by the last twelve months Total Adjusted EBITDA.
Free Cash Flow is defined as the sum of net cash provided by (used in) the following items: operating activities less capital expenditures.
Free Cash Flow per share is defined as Free Cash Flow divided by diluted weighted average common shares outstanding.
Ingevity's management also uses the above financial measures as the primary measures of profitability and liquidity of the business. In addition, Ingevity believes Adjusted EBITDA from continuing operations and Adjusted EBITDA Margin from continuing operations are useful measures because they exclude the effects of financing and investment activities as well as non-operating activities.
GAAP Reconciliation of 2026 Adjusted EBITDA Guidance
A reconciliation of net income to Adjusted EBITDA from continuing operations as projected for 2026 is not provided. Ingevity does not forecast net income as it cannot, without unreasonable effort, estimate or predict with certainty various components of net income. These components, net of tax, include further restructuring and other income (charges), net; additional acquisition and other-related (income) costs; litigation charges; additional pension and postretirement settlement and curtailment (income) charges; and revisions due to legislative tax rate changes. Additionally, discrete tax items could drive variability in our projected effective tax rate. All of these components could significantly impact such financial measures. Further, in the future, other items with similar characteristics to those currently included in Adjusted EBITDA from continuing operations, that have a similar impact on the comparability of periods, and which are not known at this time, may exist and impact Adjusted EBITDA from continuing operations.
Adjusted Earnings and Diluted Adjusted Earnings per Share Reconciliation (GAAP to Non-GAAP) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
In millions, except per share data (unaudited) |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
Net income (loss) from continuing operations (GAAP) |
$ |
39.8 |
|
|
$ |
(141.4 |
) |
|
$ |
63.2 |
|
|
$ |
(112.3 |
) |
Restructuring and other (income) charges, net (1) |
|
1.7 |
|
|
|
7.2 |
|
|
|
2.2 |
|
|
|
9.1 |
|
Goodwill impairment charge (2) |
|
— |
|
|
|
183.8 |
|
|
|
— |
|
|
|
183.8 |
|
Long-lived asset impairment charge (2) |
|
32.1 |
|
|
|
— |
|
|
|
32.1 |
|
|
|
— |
|
Gain on sale of business (3) |
|
(8.6 |
) |
|
|
— |
|
|
|
(8.6 |
) |
|
|
— |
|
Litigation charge (4) |
|
— |
|
|
|
— |
|
|
|
16.2 |
|
|
|
— |
|
Impairment of license agreement (5) |
|
— |
|
|
|
— |
|
|
|
2.8 |
|
|
|
— |
|
(Gain) loss on strategic investment (6) |
|
— |
|
|
|
2.5 |
|
|
|
— |
|
|
|
2.5 |
|
Proxy contest charges (7) |
|
— |
|
|
|
0.3 |
|
|
|
— |
|
|
|
8.2 |
|
Portfolio realignment costs (8) |
|
2.9 |
|
|
|
— |
|
|
|
6.1 |
|
|
|
— |
|
Tax effect on items above (9) |
|
(7.1 |
) |
|
|
(48.4 |
) |
|
|
(12.4 |
) |
|
|
(50.7 |
) |
Certain discrete tax provision (benefit) (10) |
|
0.7 |
|
|
|
40.9 |
|
|
|
1.3 |
|
|
|
41.3 |
|
Adjusted earnings (loss) from continuing operations (Non-GAAP) |
$ |
61.5 |
|
|
$ |
44.9 |
|
|
$ |
102.9 |
|
|
$ |
81.9 |
|
|
|
|
|
|
|
|
|
||||||||
Diluted earnings (loss) from continuing operations per share (GAAP) |
$ |
1.13 |
|
|
$ |
(3.87 |
) |
|
$ |
1.78 |
|
|
$ |
(3.08 |
) |
Restructuring and other (income) charges, net |
|
0.05 |
|
|
|
0.20 |
|
|
|
0.06 |
|
|
|
0.25 |
|
Goodwill impairment charge |
|
— |
|
|
|
5.01 |
|
|
|
— |
|
|
|
5.01 |
|
Long-lived asset impairment charge |
|
0.91 |
|
|
|
— |
|
|
|
0.90 |
|
|
|
— |
|
Gain on sale of business |
|
(0.24 |
) |
|
|
— |
|
|
|
(0.24 |
) |
|
|
— |
|
Litigation charge |
|
— |
|
|
|
— |
|
|
|
0.46 |
|
|
|
— |
|
Impairment of license agreement |
|
— |
|
|
|
— |
|
|
|
0.08 |
|
|
|
— |
|
(Gain) loss on strategic investment |
|
— |
|
|
|
0.07 |
|
|
|
— |
|
|
|
0.07 |
|
Proxy contest charges |
|
— |
|
|
|
0.01 |
|
|
|
— |
|
|
|
0.22 |
|
Portfolio realignment costs |
|
0.08 |
|
|
|
— |
|
|
|
0.17 |
|
|
|
— |
|
Tax effect on items above |
|
(0.21 |
) |
|
|
(1.32 |
) |
|
|
(0.35 |
) |
|
|
(1.37 |
) |
Certain discrete tax provision (benefit) |
|
0.02 |
|
|
|
1.12 |
|
|
|
0.03 |
|
|
|
1.13 |
|
Diluted adjusted earnings (loss) from continuing operations per share (Non-GAAP) |
$ |
1.74 |
|
|
$ |
1.22 |
|
|
$ |
2.89 |
|
|
$ |
2.23 |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding - Diluted (11) |
|
35.3 |
|
|
|
36.7 |
|
|
|
35.6 |
|
|
|
36.7 |
|
| ____________________ | |
| (1) | We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. These costs are excluded from our reportable segment results; details of which are included in the table below. For the details of these costs between our reportable segments, see Segment Operating Results on page 2. |
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
In millions |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||
Work force reductions and other |
$ |
1.3 |
|
$ |
6.5 |
|
$ |
1.0 |
|
$ |
7.7 |
Performance Chemicals repositioning |
|
0.4 |
|
|
0.7 |
|
|
1.2 |
|
|
1.4 |
Restructuring charges (i) |
|
1.7 |
|
|
7.2 |
|
|
2.2 |
|
|
9.1 |
Other (income) charges, net (i) |
|
— |
|
|
— |
|
|
— |
|
|
— |
Restructuring and other (income) charges, net (ii) |
$ |
1.7 |
|
$ |
7.2 |
|
$ |
2.2 |
|
$ |
9.1 |
_________________ |
|||||||||||
(i) Amounts are recorded within Restructuring and other (income) charges, net on the condensed consolidated statement of operations. |
|||||||||||
(ii) For information on our Workforce reductions and other and our Performance Chemicals' repositioning please refer to Note 11, Restructuring and Other (Income) Charges, net, in the Notes to the Condensed Consolidated Financial Statements included in the Company’s Form 10-Q for the quarter ended March 31, 2026, filed on May 7, 2026. Updates will be provided in subsequent filings of the Company's Form 10-Q in 2026. |
|||||||||||
(2) |
The company recorded a non-cash impairment charge within Advanced Polymer Technologies. |
(3) |
The gain relates to the sale of our former Performance Chemicals' road markings product line on April 15, 2026. |
(4) |
For information on our litigation charges please refer to Note 13, Commitments and Contingencies, in the Notes to the Condensed Consolidated Financial Statements included in the Company’s Form 10-Q for the quarter ended March 31, 2026, filed on May 7, 2026. Updates will be provided in subsequent filings of the Company's Form 10-Q in 2026. |
(5) |
Charge represents an impairment of a license agreement within our Performance Materials reportable segment. |
(6) |
We exclude gains and losses from sales of strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses to be directly associated with the operational performance of the segment. We believe that the inclusion of such gains or losses, would impair the factors and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our reportable segment results. The charge relates to our Advanced Polymer Technologies reportable segment. |
(7) |
Charges represent legal and other professional service fees as well as incremental proxy solicitation costs related to a proxy contest. |
(8) |
Charges represent professional service fees related to a review of the company's portfolio. |
(9) |
Income tax impact of non-GAAP adjustments is the summation of the calculated income tax charge related to each pre-tax non-GAAP adjustment. The non-GAAP adjustments relate primarily to adjustments in |
(10) |
Represents certain discrete tax items such as excess tax benefits on stock compensation and impacts of legislative tax rate changes. |
(11) |
The average number of shares outstanding used in the three and six months ended 2025 diluted adjusted earnings (loss) per share computation (Non-GAAP) includes 0.2 and 0.3 million diluted shares, respectively. This number of shares differs from the average number of shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a net loss on a GAAP basis. |
Adjusted EBITDA Reconciliation (GAAP to Non-GAAP) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
In millions, except percentages (unaudited) |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||||
Net income (loss) from continuing operations (GAAP) |
$ |
39.8 |
|
|
$ |
(141.4 |
) |
|
$ |
63.2 |
|
|
$ |
(112.3 |
) |
Provision (benefit) for income taxes on continuing operations |
|
10.9 |
|
|
|
4.8 |
|
|
|
17.7 |
|
|
|
13.3 |
|
Interest expense, net |
|
14.2 |
|
|
|
18.6 |
|
|
|
30.1 |
|
|
|
38.0 |
|
Depreciation and amortization |
|
22.0 |
|
|
|
25.2 |
|
|
|
44.7 |
|
|
|
49.7 |
|
Restructuring and other (income) charges, net (1) |
|
1.7 |
|
|
|
7.2 |
|
|
|
2.2 |
|
|
|
9.1 |
|
Goodwill impairment charge (1) |
|
— |
|
|
|
183.8 |
|
|
|
— |
|
|
|
183.8 |
|
Long-lived asset impairment charge (1) |
|
32.1 |
|
|
|
— |
|
|
|
32.1 |
|
|
|
— |
|
Gain on sale of business (1) |
|
(8.6 |
) |
|
|
— |
|
|
|
(8.6 |
) |
|
|
— |
|
Litigation charge (1) |
|
— |
|
|
|
— |
|
|
|
16.2 |
|
|
|
— |
|
Impairment of license agreement (1) |
|
— |
|
|
|
— |
|
|
|
2.8 |
|
|
|
— |
|
(Gain) loss on strategic investments |
|
— |
|
|
|
2.5 |
|
|
|
— |
|
|
|
2.5 |
|
Proxy contest charges (1) |
|
— |
|
|
|
0.3 |
|
|
|
— |
|
|
|
8.2 |
|
Portfolio realignment costs (1) |
|
2.9 |
|
|
|
— |
|
|
|
6.1 |
|
|
|
— |
|
Adjusted EBITDA from continuing operations (Non-GAAP) |
$ |
115.0 |
|
|
$ |
101.0 |
|
|
$ |
206.5 |
|
|
$ |
192.3 |
|
|
|
|
|
|
|
|
|
||||||||
Net income (loss) from discontinued operations (GAAP) |
$ |
(4.5 |
) |
|
$ |
(5.1 |
) |
|
$ |
31.9 |
|
|
$ |
(13.7 |
) |
Provision (benefit) for income taxes on discontinued operations |
|
(1.7 |
) |
|
|
(1.0 |
) |
|
|
9.7 |
|
|
|
(3.2 |
) |
Depreciation and amortization |
|
— |
|
|
|
0.4 |
|
|
|
— |
|
|
|
0.8 |
|
Restructuring and other (income) charges, net (1) |
|
4.8 |
|
|
|
14.7 |
|
|
|
12.6 |
|
|
|
25.1 |
|
Gain on sale of business (1) |
|
1.4 |
|
|
|
— |
|
|
|
(54.2 |
) |
|
|
— |
|
Adjusted EBITDA from discontinued operations (Non-GAAP) |
$ |
— |
|
|
$ |
9.0 |
|
|
$ |
— |
|
|
$ |
9.0 |
|
|
|
|
|
|
|
|
|
||||||||
Total Adjusted EBITDA (Non-GAAP) |
$ |
115.0 |
|
|
$ |
110.0 |
|
|
$ |
206.5 |
|
|
$ |
201.3 |
|
|
|
|
|
|
|
|
|
||||||||
Net sales from continuing operations |
$ |
314.1 |
|
|
$ |
331.5 |
|
|
$ |
572.1 |
|
|
$ |
579.4 |
|
Net income (loss) margin from continuing operations |
|
12.7 |
% |
|
|
(42.7 |
)% |
|
|
11.0 |
% |
|
|
(19.4 |
)% |
Adjusted EBITDA margin from continuing operations (Non-GAAP) |
|
36.6 |
% |
|
|
30.5 |
% |
|
|
36.1 |
% |
|
|
33.2 |
% |
|
|
|
|
|
|
|
|
||||||||
Net sales from discontinued operations |
$ |
— |
|
|
$ |
33.6 |
|
|
$ |
— |
|
|
$ |
69.7 |
|
Net income (loss) margin from discontinued operations |
|
— |
% |
|
|
(15.2 |
)% |
|
|
— |
% |
|
|
(19.7 |
)% |
Adjusted EBITDA margin from discontinued operations (Non-GAAP) |
|
— |
% |
|
|
26.8 |
% |
|
|
— |
% |
|
|
12.9 |
% |
|
|
|
|
|
|
|
|
||||||||
Total Net sales (Non-GAAP) |
$ |
314.1 |
|
|
$ |
365.1 |
|
|
$ |
572.1 |
|
|
$ |
649.1 |
|
Net income (loss) as a percentage of Total Net sales |
|
11.2 |
% |
|
|
(40.1 |
)% |
|
|
16.6 |
% |
|
|
(19.4 |
)% |
Total Adjusted EBITDA margin (Non-GAAP) |
|
36.6 |
% |
|
|
30.1 |
% |
|
|
36.1 |
% |
|
|
31.0 |
% |
| _________________ | |
(1) |
For more information on these charges, refer to the Adjusted Earnings Reconciliation (GAAP to Non-GAAP) table on page 8. |
Free Cash Flow Calculation (Non-GAAP) |
|||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||
In millions (unaudited) |
2026 |
|
2025 |
|
2026 |
|
2025 |
||||||
Net cash provided by (used in) operating activities |
$ |
(13.8 |
) |
|
$ |
79.0 |
|
$ |
(15.8 |
) |
|
$ |
104.4 |
Less: Litigation Settlement Payment (1) |
|
(113.2 |
) |
|
|
— |
|
|
(113.2 |
) |
|
|
— |
Less: Capital expenditures |
|
10.3 |
|
|
|
12.2 |
|
|
20.6 |
|
|
|
22.2 |
Free Cash Flow (Non-GAAP) |
$ |
89.1 |
|
|
$ |
66.8 |
|
$ |
76.8 |
|
|
$ |
82.2 |
|
|
|
|
|
|
|
|
||||||
Free Cash Flow per share (Non-GAAP) |
$ |
2.52 |
|
|
$ |
1.82 |
|
$ |
2.16 |
|
|
$ |
2.24 |
|
|
|
|
|
|
|
|
||||||
Weighted average common shares outstanding - Diluted (2) |
|
35.3 |
|
|
|
36.7 |
|
|
35.6 |
|
|
|
36.7 |
| _________________ | |
(1) |
For the three and six months ended June 30, 2026, Free Cash Flow excludes a litigation settlement payment. For more information, refer to the Notes to the Condensed Consolidated Financial Statements included in the Company’s Form 10-Q for the period ended March 31, 2026, filed on May 7, 2026. Updates will be provided in subsequent filings of the Company's Form 10-Q in 2026. |
(2) |
The average number of shares outstanding used in the three and six months ended 2025 diluted adjusted earnings (loss) per share computation (Non-GAAP) includes 0.2 and 0.3 million diluted shares, respectively. This number of shares differs from the average number of shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a net loss on a GAAP basis. |
Net Debt Ratio Calculation (Non-GAAP) |
|||
In millions, except ratios (unaudited) |
June 30, 2026 |
||
Notes payable and current maturities of long-term debt |
$ |
144.0 |
|
Long-term debt including finance lease obligations |
|
1,056.2 |
|
Debt issuance costs |
|
2.6 |
|
Total Debt |
|
1,202.8 |
|
Less: |
|
||
Cash and cash equivalents (1) |
|
97.5 |
|
Restricted investment (2) |
|
85.8 |
|
Net Debt |
$ |
1,019.5 |
|
|
|
||
Net Debt Ratio (Non-GAAP) |
|
||
Adjusted EBITDA (Non-GAAP) |
|
||
Twelve months ended December 31, 2025 - Total Adjusted EBITDA |
$ |
397.5 |
|
Six months ended June 30, 2025 (3) - Total Adjusted EBITDA |
|
(201.3 |
) |
Six months ended June 30, 2026 (3) - Total Adjusted EBITDA |
|
206.5 |
|
Total Adjusted EBITDA (Non-GAAP) - last twelve months (LTM) as of June 30, 2026 |
$ |
402.7 |
|
|
|
||
Net debt ratio (Non-GAAP) |
2.5x |
||
| _________________ | |
(1) |
Includes |
(2) |
Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' |
(3) |
Refer to the Adjusted EBITDA Reconciliation (GAAP to Non-GAAP) schedule on page 10 for the reconciliation to the most comparable GAAP financial measure. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260729575881/en/
Caroline Monahan
843-740-2068
media@ingevity.com
Investors:
Mickey Walsh
843-740-2002
investors@ingevity.com
Source: Ingevity Corporation